logo
Best Delta 8 Gummies For Euphoria by Candy Cloud in 2025

Best Delta 8 Gummies For Euphoria by Candy Cloud in 2025

Yahoo15-05-2025

LOS ANGELES, May 15, 2025 (GLOBE NEWSWIRE) -- Search interest for Delta-8 THC has grown over 800% since 2020, and gummies dominate those queries. According to Google Trends and retail data, gummies now outpace cartridges, tinctures, and softgels in online sales. But the real question is: which ones are actually effective and safe? A recent study found that 60% of Delta-8 products tested didn't match their label claims. Some were underdosed, others contaminated. With no FDA regulation and minimal state oversight in most areas, finding quality gummies isn't as easy as scrolling through a product page.The best Delta-8 gummies are third-party lab tested, accurately dosed, and use clean extraction from hemp—not synthetic conversions. In this list, we've done the legwork—cutting through 40+ products to bring you the few that deliver on effects, taste, and verified purity. This is what you should actually be putting in your cart.
Best Delta 8 Gummies in the Market
Delta 8 THC Gummies
D8, D9, D10 Extra Strength Gummies
Blue Lotus + Delta 8 THC Gummies
1. Candy Cloud's Delta 8 THC Gummies - Overall Best Candy Cloud's Delta 8 Strawberry Gummies rank at the top for their purity, potency options, and ingredient transparency. They're available in three strengths: 750mg, 1500mg, and 3000mg per jar, each containing 30 gummies. That breaks down to 25mg, 50mg, or 100mg per gummy—ideal for both low-tolerance and high-tolerance users. Each dose delivers consistent effects due to proper homogenization and verified third-party lab testing. Many Delta 8 products fall short on accurate dosing, but this one delivers what's promised on the label.
The formula is entirely vegan and organic, with no gelatin, no high-fructose corn syrup, and no artificial flavors or synthetic dyes. That alone puts it several steps above most store-bought Delta 8 options. The gummies are sweetened with natural alternatives and contain no GMO ingredients, making them better suited for health-conscious buyers who don't want chemical-laced edibles.
Key Specifications:
Potency Options: 25mg, 50mg, or 100mg of Delta-8 THC per gummy
Jar Size: 30 gummies per jar
Dietary Profile: Vegan, gelatin-free, gluten-free, non-GMO
Sweeteners & Additives: No high-fructose corn syrup, no synthetic colors or artificial sweeteners
Testing & Certification: Third-party lab tested for potency, solvents, and contaminants
Pros: – Three strength options make it flexible for different dosing needs – Uses high-quality, plant-based ingredients – Clean formula—free of animal products, artificial additives, and cheap fillers – Clear COAs (Certificates of Analysis) provided for every batch – Subscription model offers 25% savings for recurring orders
Cons: – Only available in one flavor (Strawberry)
Unlike many brands that focus on flavor gimmicks or flashy packaging, this product emphasizes clean extraction, accurate dosing, and food-safe ingredients. It's made in the USA under quality-controlled conditions, which reflects in both user reviews and lab reports.
For users who want strong, predictable Delta 8 effects without questionable additives, this gummy is a clear choice. It offers a balance of safety, strength, and quality that many others miss.
Visit Candy Cloud to Buy Delta 8 Gummies>>
2. D8, D9, D10 Extra Strength Gummies – Most Potent Delta-8 EdiblesThis triple-blend gummy combines Delta 8, Delta 9, and Delta 10 THC in one formula—designed for users who want a more layered and potent effect. Each piece delivers 125mg total cannabinoids: 75mg Delta-8, 15mg Delta-9, and 35mg Delta-10. That's significantly higher than most standard gummies, which typically top out at 25–50mg of a single cannabinoid. This makes it one of the most powerful edible options in its class.
Despite the high dose, the formula stays clean: vegan, gelatin-free, gluten-free, and made with all-natural ingredients. No artificial colors, no synthetic sweeteners, no high-fructose corn syrup. It's also lab-tested to confirm potency and purity, with COAs available for each batch. Those who use cannabinoids for stronger body effects, mental focus, or longer-lasting relief may benefit from this blend's unique ratio and extended release.
Key Specifications:
Cannabinoid Content: 75mg Delta-8, 15mg Delta-9, 35mg Delta-10 per gummy
Total Per Piece: 125mg cannabinoids
Formula Profile: Vegan, gelatin-free, gluten-free, non-GMO
Additives: No synthetic sweeteners or artificial colors
Testing: Full-panel third-party lab tested
Pros: – One of the highest-potency edibles available – Multi-cannabinoid effect: balanced head/body sensation – No animal-derived ingredients or harmful additives – Lab-tested and made in the USA – Subscription option saves 25%
Cons: – May be too strong for low-tolerance users
This is not a beginner-friendly product, but for experienced users looking for stronger, layered effects, it delivers on all fronts. The triple blend offers a mix of body relaxation (Delta-8), mild euphoria (Delta-9), and a subtle mental lift (Delta-10)—all in one gummy. Backed by clean sourcing, transparent testing, and a 60-day guarantee, it's a reliable second pick for those who want more than just Delta-8.
3. Blue Lotus + Delta 8 THC Gummies – Top-Rated Delta 8 Gummies For CalmThis formula combines two potent plant-based compounds—150mg Blue Lotus extract and 150mg Delta 8 THC extract per gummy—for a dual-effect experience. Blue Lotus, a botanical known for promoting calm and introspective clarity, is paired with Delta 8's smooth euphoric effects to create a uniquely balanced outcome. This gummy is ideal for users seeking a blend that supports relaxation without sacrificing mental awareness.
The ingredient list avoids all artificial sweeteners, dyes, or fillers. It's vegan, gelatin-free, gluten-free, and made with non-GMO inputs. That makes it suitable for people who care about clean consumption. No high-fructose corn syrup, no synthetic colors, and no chemical preservatives are included. Each gummy is lab-tested for both cannabinoid accuracy and botanical purity, with all COAs publicly available.
Key Specifications:
Active Ingredients: 150mg Delta 8 THC + 150mg Blue Lotus extract per gummy
Formula Type: Vegan, gluten-free, gelatin-free, non-GMO
Additive-Free: No synthetic colors, sweeteners, or preservatives
Testing: Third-party lab verified
Use Case: Calm focus + light euphoria
Pros:
– Balanced botanical-cannabinoid synergy – High dosage of both Delta 8 and Blue Lotus – No animal-based or artificial ingredients – Transparent lab results for each batch – 60-day money-back guarantee
Cons: – May be too calming for daytime use
For those looking beyond standard edibles, this combo of blue lotus and Delta 8 brings together heritage plant medicine and lab-tested cannabinoids in a way few products do. The effects are smoother than pure Delta 8 alone, with a mellow onset and sustained calm. Ideal for evenings, low-stimulation environments, or reflective sessions. This blend serves a different purpose than typical gummies—and does it with clean, reliable ingredients
Benefits of Delta 8 THC
Delta 8 THC is a cannabinoid derived from hemp that interacts with the body's endocannabinoid system in ways that can produce both physical and mental effects. Though it shares some similarities with Delta 9 THC, Delta 8 is often described as having a more balanced and manageable impact. Its benefits are gaining attention not just from users, but also from researchers studying its potential therapeutic properties.
Milder Psychoactive Effects
Delta 8 THC binds to the same CB1 receptors as Delta 9, but with less intensity. This often results in a gentler high—clearer headspace, lighter euphoria, and reduced paranoia. For those sensitive to Delta 9 or prone to anxiety, Delta 8 offers a smoother alternative that still delivers mental elevation without an overpowering effect.
Supports Appetite and Digestion
Research and user feedback suggest Delta 8 can increase appetite, similar to Delta 9, but without the extreme munchies or brain fog. It may also help reduce nausea and support digestive comfort, making it potentially useful for those undergoing treatments like chemotherapy or those with chronic stomach discomfort.
Promotes Relaxation and Sleep
Many users report feeling physically relaxed and mentally calm after taking Delta 8. Its interaction with CB1 receptors may help regulate stress responses and support deeper, more restorative sleep. It's particularly noted for helping people wind down in the evening without leaving them groggy the next day.
May Aid Pain and Inflammation Management
Delta 8 has shown promise in early studies for reducing inflammation and pain. By binding to CB1 and CB2 receptors, it may modulate how the body processes pain signals. People with joint stiffness, migraines, or chronic pain conditions often report reduced discomfort and better mobility after use.
Enhances Mood and Focus
Unlike high doses of Delta 9, which can cause racing thoughts or distraction, Delta 8 may enhance mood without causing mental chaos. Some users describe feeling uplifted, more present, and better able to focus on tasks. It's often used during low-intensity work, creative sessions, or even light social activity.
Delta 8 THC offers a range of physical and psychological effects that many find beneficial for daily support. Always start with a low dose to assess tolerance and ensure effects align with personal needs.
How to Choose the Best Delta 8 Gummies
With so many Delta 8 THC gummies available, choosing the right one can be the difference between a smooth, enjoyable experience and complete disappointment. Potency, purity, ingredients, and actual performance vary across brands. Here are five key factors to consider before buying:
Check Third-Party Lab Testing
Lab results aren't optional—they're essential. Always choose gummies that come with up-to-date Certificates of Analysis (COAs) from independent labs. These reports should confirm Delta 8 content, screen for heavy metals, pesticides, solvents, and microbial contaminants. Brands that don't publish COAs or only offer potency testing without safety screenings should be avoided.
Understand the Dosage Per Gummy
Delta 8 gummies range from 10mg to over 100mg per piece. Beginners may prefer 10–25mg, while experienced users often reach for 50mg or more. Clear labeling matters—some brands list total content per jar but not per gummy. Be sure you know what each piece contains to avoid accidental overconsumption and to ensure predictable effects.
Review the Ingredient List
Clean formulations are easier on the body. Look for gummies made with natural sweeteners, plant-based pectin instead of gelatin, and free from high-fructose corn syrup or artificial colors. Vegan, gluten-free, and non-GMO labels are good indicators of quality, especially for long-term use. Avoid those with chemical preservatives or synthetic additives.
Evaluate Brand Transparency and Sourcing
A trustworthy brand will clearly explain where its hemp is grown, how the Delta 8 is extracted, and how each batch is produced. Look for products made in GMP-certified facilities within the USA, as this usually ensures better control over purity and process. Avoid vague websites or companies with no background information.
Read Verified Customer Reviews
Don't rely solely on marketing claims. Real user feedback can reveal patterns in taste, texture, onset time, and actual effects. Pay attention to reviews that mention consistent dosing, no aftertaste, and repeat purchases. Be cautious if most reviews sound generic or overly promotional—it's often a sign of filtered or fake feedback.
Side Effects and Risks of Delta 8 THC
Delta 8 THC may offer milder effects than Delta 9, but it's not free from side effects. The most reported issues include dry mouth, red eyes, drowsiness, and slight dizziness—especially at higher doses. Some users experience delayed onset and unintentionally take more, leading to overconsumption.
In certain cases, Delta 8 can cause temporary confusion, increased heart rate, or anxiety, particularly for those who are sensitive to THC. These effects are usually short-lived but can be uncomfortable. Overuse may impair coordination and reaction time, making it unsafe to drive or operate machinery after consumption.
Another concern is product quality. Because Delta 8 is often synthesized from CBD through chemical conversion, poor manufacturing practices can leave behind residual solvents or byproducts. That makes third-party lab testing essential to avoid harmful contaminants.
Frequent use can also lead to tolerance, reducing effectiveness over time and encouraging higher doses, which may raise the risk of unwanted effects. Those with pre-existing conditions or on medications should consult a healthcare provider before use. Delta 8 may interact with certain drugs or affect blood pressure, mood, or liver function. Responsible dosing and quality sourcing help reduce most of these risks.
Delta 8 vs Other Cannabinoids
Delta 8 THC is often compared with other major cannabinoids like Delta 9 THC, CBD, Delta 10, and HHC. Each interacts with the body's endocannabinoid system differently, resulting in distinct effects, benefits, and tolerability.
Delta 8 vs Delta 9 THCDelta 8 and Delta 9 are chemically similar, but Delta 8 has a double bond on the 8th carbon chain instead of the 9th. This small difference reduces its psychoactive strength. Delta 8 tends to produce a lighter, more clear-headed experience with lower chances of anxiety or paranoia, while Delta 9 is stronger, faster acting, and more likely to cause intense effects. Those sensitive to Delta 9 often find Delta 8 more manageable.
Delta 8 vs CBDCBD is non-psychoactive and works mainly through indirect receptor pathways. It does not produce a high but may help reduce inflammation, stress, or discomfort. Delta 8, by contrast, binds to CB1 receptors and produces mild intoxication. While both may assist with sleep, appetite, and mood, the presence of psychoactive effects makes Delta 8 a different experience entirely. People often use CBD during the day and reserve Delta 8 for evening use.
Delta 8 vs Delta 10 THCDelta 10 is another THC isomer like Delta 8 but tends to produce a more energetic or mentally stimulating outcome. Delta 8 is usually preferred for calming physical effects and mild euphoria, while Delta 10 may lean toward alertness or mental clarity. Most users describe Delta 8 as body-focused and Delta 10 as head-focused. They are sometimes combined for balanced results.
Delta 8 vs HHC (Hexahydrocannabinol)HHC is hydrogenated THC with a structure that makes it more stable and resistant to degradation. It's closer in potency to Delta 9 and produces effects that many describe as smoother but more intense than Delta 8. HHC may last longer in the system and hit harder, depending on the dose. Delta 8 has a shorter effect window and tends to be more predictable for daily use.
How to Dose Delta 8 Gummies
Delta 8 THC gummies vary in strength, so accurate dosing is essential for safe and effective use. The ideal dose depends on factors like body weight, THC tolerance, and intended effect. Start low and increase gradually over time—this reduces the risk of side effects such as dizziness or grogginess.
Beginners should start with 5–10mg of Delta 8 THC. This may mean taking one-quarter or half of a 25mg gummy. Wait at least 2 hours before deciding to take more. Edibles take longer to absorb, and effects may build slowly.
Moderate users with some THC experience often settle in the 15–40mg range. This level can provide stronger relaxation or euphoria without overwhelming the system. Always check the label—some gummies contain 50mg or more and taking a full piece without preparation can lead to overconsumption.
Experienced users who are tolerant to THC may use 50–100mg or higher, but this should only be done with products that have clear lab testing and ingredient transparency. Doses above 100mg increase the chance of strong sedation or mental fog.
Gummies can vary in absorption rate depending on ingredients. Those made with fats or emulsifiers may activate faster. Always consume Delta 8 gummies with awareness of timing, dose, and personal sensitivity. Start low. Go slow. Adjust only after the full effect is felt.
Is Delta 8 THC Legal?
Delta 8 THC is federally legal in the United States when derived from hemp that contains less than 0.3% Delta 9 THC, according to the 2018 Farm Bill. This classification allows for the production and sale of Delta 8 products, as long as they are sourced from legal hemp and not synthetically converted from non-hemp materials. The Ninth Circuit Court of Appeals reinforced this federal status in 2022 by ruling that hemp-derived Delta 8 meets the legal definition of hemp under U.S. law.
However, individual states have full authority to regulate or ban Delta 8 THC, and many have. As of 2025, states like Alaska, Colorado, New York, and Vermont have banned Delta 8 entirely. Others, such as California, Michigan, and Florida, have set up regulatory frameworks requiring testing, age restrictions, and labeling standards.
Some states operate in a grey zone, where Delta 8 is not officially banned but is subject to changing policies or pending legislation. Retailers and consumers in those states face shifting rules that can affect availability. Online sales remain common, but shipping is typically blocked to banned states.
Before purchasing, it's critical to check the specific legal status of Delta 8 in your state. Federal legality does not override state restrictions, and enforcement can vary widely.
FAQs About Delta-8 Gummies
Q. What is the best brand of Delta 8 gummies?
One of the best-performing Delta 8 gummy brands is Candy Cloud. It offers multiple strengths, blends, and lab-tested formulas using vegan, non-GMO, and additive-free ingredients. Their products include options with Delta 8 only, Delta 8 + Delta 9 + Delta 10, and Delta 8 with Blue Lotus. Each batch is backed by third-party testing for potency and purity. Gummies range from 25mg to 125mg per piece, allowing flexible dosing. The brand avoids artificial colors, gelatin, and high-fructose corn syrup.
Q. Are Delta 8 or Delta 9 edibles stronger?
Delta 9 edibles are stronger. Delta 9 THC has a higher binding affinity to CB1 receptors in the brain, producing more intense psychoactive effects. A 10mg Delta 9 gummy typically delivers a noticeably stronger high than a 10mg Delta 8 gummy. Delta 8 tends to produce milder, more clear-headed effects. Those who are sensitive to THC often prefer Delta 8 due to its lower risk of anxiety, paranoia, or overstimulation. However, higher doses of Delta 8 can still produce significant intoxication. Always compare actual milligram content before assuming similar effects between the two.
Q. Does Delta 8 show up on drug tests?
Yes, Delta 8 THC can show up on drug tests. Standard urine tests detect THC metabolites, and Delta 8 produces the same primary metabolite (THC-COOH) as Delta 9. These tests do not typically differentiate between types of THC. Even small amounts of Delta 8 can trigger a positive result on a drug screening. Detection time varies based on frequency of use, body fat, and metabolism but can last from several days to over a week. Individuals subject to workplace testing or legal screenings should avoid all THC products, including hemp-derived Delta 8.
Q. How long do Delta 8 gummies' effects usually last?
Delta 8 gummies usually start working within 30 to 90 minutes, with effects peaking around 2 to 3 hours after ingestion. The total duration can range from 4 to 8 hours depending on dosage, metabolism, and individual tolerance. Higher doses may last longer and produce more pronounced effects. Users report a slow, steady onset and a gradual decline, which makes Delta 8 edibles suitable for sustained experiences. Because of their delayed onset, it's recommended to avoid redosing too soon. Always wait at least 2 hours before deciding to take more.
Q. How should I store Delta 8 gummies?
Delta 8 gummies should be kept in a cool, dry, and dark place to preserve their strength, taste, and texture. Avoid leaving them near windows, stoves, or other spots with direct light or heat, as these can cause the gummies to melt or lose potency over time. Keep the container tightly sealed to protect against air and moisture, which can make the gummies sticky or degrade the cannabinoids. Original packaging is usually designed for storage, but airtight jars or containers also work well. Skip humid areas like bathrooms or kitchens and store them somewhere stable and shaded.
Conclusion: Where to Buy Delta 8 Gummies?
Buy Delta 8 gummies only from trusted brands that provide verified third-party lab results, clear ingredient labels, and transparent sourcing. Online stores like Candy Cloud offer a wide range of Delta 8 products with options for different potencies and blends, all made with vegan, non-GMO ingredients. Look for products that are free from artificial additives, gelatin, and corn syrup. Always check state laws before placing an order, as shipping restrictions may apply. Avoid buying from unverified vendors or gas stations, where product quality and labeling are often unreliable or inconsistent. Quality and safety should come first.
Media Details :
Company: Candy Cloud
Company Website: https://trycandycloud.com/
Contact Person: Emilla
Email ID: emilla@trycandycloud.com
Disclaimer: The statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Always consult a healthcare professional before taking any dietary supplements.
Disclosure: This article is for informational purposes only and does not constitute medical advice. The content may include affiliate links, meaning we may earn a commission if you purchase through recommended links. Always consult a healthcare professional before starting any new supplement regimen.
Photos accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/ca9c9fef-61cb-405a-a2ed-a67264944cb3https://www.globenewswire.com/NewsRoom/AttachmentNg/a70f69ec-3e14-4042-b31e-42c91900df7bhttps://www.globenewswire.com/NewsRoom/AttachmentNg/5c5ce6e2-63dc-457c-b32a-dfebb03cb361https://www.globenewswire.com/NewsRoom/AttachmentNg/8c5fec8f-67a6-4456-b543-dbd4f4db21af

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Associated Press

time19 minutes ago

  • Associated Press

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant. 'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.' Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine. About the VERITAC-2 Clinical Trial The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint. About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]

Canada Glucose Monitoring Device Market Forecast & Opportunities, 2025-2030: Increasing Adoption of Advanced Glucose Monitoring Technologies
Canada Glucose Monitoring Device Market Forecast & Opportunities, 2025-2030: Increasing Adoption of Advanced Glucose Monitoring Technologies

Yahoo

time28 minutes ago

  • Yahoo

Canada Glucose Monitoring Device Market Forecast & Opportunities, 2025-2030: Increasing Adoption of Advanced Glucose Monitoring Technologies

The Canada glucose monitoring device market is expanding due to rising diabetes cases and technological advancements. Key opportunities include increased demand for continuous and flash glucose monitors for proactive management. However, high costs limit access, especially for uninsured patients. Advanced CGMs and data-integrated solutions offer growth potential. Canadian Glucose Monitoring Device Market Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Canada Glucose Monitoring Device Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Canada Glucose Monitoring Device Market was valued at USD 1.23 Billion in 2024 and is expected to reach USD 2.54 Billion by 2030, rising at a CAGR of 12.85% The market is witnessing significant expansion driven by rapid technological advancements and the rising prevalence of diabetes across the country. With diabetes recognized as a pressing public health concern, demand for efficient glucose monitoring tools has surged. According to Health Canada, the global diabetic population is expected to more than double by 2050, underscoring the urgent need for accessible monitoring solutions. As a major contributor to global morbidity and mortality, diabetes has propelled the adoption of devices like continuous and flash glucose monitors, which offer real-time data and enable proactive disease management. Rising Prevalence of Diabetes in Canada The growing number of diabetes cases across Canada is a critical factor driving the glucose monitoring device market. By 2020-2021, approximately 3.7 million Canadians, or 9.4% of the population aged one and above, were diagnosed with diabetes, a figure that climbs to 27% among those aged 65 and older. This demographic shift underscores the escalating need for effective blood sugar monitoring tools. Devices such as continuous glucose monitors (CGMs) and flash glucose monitors (FGMs) have become essential for real-time tracking and management of glucose levels. They support timely interventions and help mitigate complications like cardiovascular disease, kidney damage, and neuropathy, thereby improving patient outcomes and quality of life. High Cost of Advanced Monitoring Devices The cost of advanced glucose monitoring technologies remains a major hurdle to widespread use. While some government programs offer financial assistance, not all individuals qualify, and personal expenses can be steep. For instance, individuals with type 1 diabetes in Alberta may face up to $7,000 in annual out-of-pocket expenses, while those with type 2 diabetes could spend as much as $6,000. These costs include the initial device, sensors, and transmitters, which can be financially burdensome for patients lacking sufficient insurance coverage. This financial barrier often restricts access to newer technologies, affecting diabetes care and control among economically vulnerable populations. Adoption of Advanced Glucose Monitoring Technologies A prominent trend in the Canadian market is the increasing shift towards advanced glucose monitoring systems, particularly CGMs. These devices deliver continuous glucose readings, offering superior glycemic management and reducing complications such as hypo- and hyperglycemia. Compared to traditional finger-prick methods, CGMs enhance user convenience and improve quality of life. Integration with insulin pumps and mobile apps has enabled real-time data sharing and automated insulin delivery, allowing healthcare providers to personalize treatment plans more effectively. As awareness of these benefits grows, the uptake of advanced glucose monitoring technologies is expected to rise steadily across Canada. Key Attributes: Report Attribute Details No. of Pages 70 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.23 Billion Forecasted Market Value (USD) by 2030 $2.54 Billion Compound Annual Growth Rate 12.8% Regions Covered Canada Report Scope Key Market Players: Medtronic of Canada Ltd Abbott Canada. Johnson & Johnson Inc/Canada Braun of Canada F. Hoffmann-La Roche Limited. Ascensia Diabetes Care. Sanofi-Aventis Canada Inc. Eli Lilly Canada Inc. Canada Glucose Monitoring Device Market, By Product Type: Self-Blood Glucose Monitoring Devices Continuous Glucose Monitoring Devices Canada Glucose Monitoring Device Market, By Application: Type 1 Diabetes Type 2 Diabetes Gestational Diabetes Canada Glucose Monitoring Device Market, By End User: Home Care Settings Hospital Others Canada Glucose Monitoring Device Market, By Region: Ontario Quebec Alberta British Columbia Saskatchewan and Manitoba Rest of Canada For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Canadian Glucose Monitoring Device Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today

Yahoo

timean hour ago

  • Yahoo

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today

We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday's best-performing stocks. ImmunityBio extended its winning streak to a fifth consecutive day on Wednesday, jumping 8.1 percent to finish at $2.93 apiece as investors cheered the Food and Drug Administration's (FDA) green light for the company to expand the access of its Anktiva treatment to patients with solid tumors. According to ImmunityBio, Inc. (NASDAQ:IBRX), it was granted by the FDA to treat lymphopenia in adult patients with refractory or relapsed solid tumors. 'Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed,' said ImmunityBio, Inc. (NASDAQ:IBRX) founder and Executive Chairman Patrick Soon-Shiong. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. 'This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA. The survival benefit we observed at ASCO 2025 in 3rd to 6th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels, rather than depleting them, can change the course of disease.' Following the announcement, the company earned a 'buy' recommendation and a price target of $8 from investment firm HC Wainwright. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store